Cadrenal Therapeutics CVKD
NASDAQ CVKD
$1.35 -0.09 (-6.21%)
As of: Nov 11, 2026 · 1:07 PM EST

Cadrenal Therapeutics (CVKD) Return on Assets [ROA] (2023 - 2026)

Updated

Cadrenal Therapeutics (CVKD) reported Return on Assets [ROA] of -279.03% for Q2 2026, down 133.59 percentage points from -145.44% a year earlier.

Analysis

Cadrenal Therapeutics (CVKD) Return on Assets [ROA] (2023 - 2026) Analysis & Trends

For FY2023, Cadrenal Therapeutics posted Return on Assets [ROA] of -158.83%.

  • The Q2 2026 figure ranks as the lowest quarterly Return on Assets [ROA] in data going back to Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 19.00%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.08%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 7.32%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 1.87%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.36%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 9.80%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -7.67%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 2.00%
10 Cadrenal Therapeutics 557,746.58 -12.06 Mn - -273.19%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -273.19%
Mar 31, 2026 -330.75%
Dec 31, 2025 -314.64%
Sep 30, 2025 -285.82%
Jun 30, 2025 -202.53%
Mar 31, 2025 -141.99%
Dec 31, 2024 -143.91%
Sep 30, 2024 -150.11%
Jun 30, 2024 -99.74%
Mar 31, 2024 -62.27%
Dec 31, 2023 -82.86%
Sep 30, 2023 -114.02%
Jun 30, 2023 -181.25%
Mar 31, 2023 -257.52%
API Access

Cadrenal Therapeutics Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=CVKD&period=max&api_key=YOUR_API_KEY